Pfizer (PFE) Cash & Current Investments (2009 - 2026)

Pfizer (PFE) has reported Cash & Current Investments for 18 consecutive years, with $11.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Current Investments fell 11.7% year-over-year to $11.7 billion in Q2 2026; TTM through Jun 2026 was $11.7 billion, a 11.7% decrease from a year earlier, with the FY2025 full-year figure at $13.6 billion, down 33.6% from the prior year.
• Cash & Current Investments was $11.7 billion for Q2 2026 at Pfizer, down from $13.1 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $44.8 billion in Q3 2023 and troughed at $7.1 billion in Q2 2024.
• A 5-year average of $18.2 billion and a median of $14.3 billion in 2025 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments tumbled 84.15% in 2024 and jumped 86.61% in 2025, its largest moves.
• Over 5 years, Cash & Current Investments stood at $22.7 billion in 2022, then slumped by 44.18% to $12.7 billion in 2023, then jumped by 61.36% to $20.5 billion in 2024, then plunged by 33.6% to $13.6 billion in 2025, then decreased by 13.95% to $11.7 billion in 2026.
• The last three Cash & Current Investments figures came in at $11.7 billion (Q2 2026), $13.1 billion (Q1 2026), and $13.6 billion (Q4 2025), per Business Quant data.